LIFNano™ holds a robust intellectual property position
Investment
LIFNanoRx Ltd is the world's first Synthetic Stem Cell Company, capturing the power of stem cells inside tiny nanoparticles of FDA-approved gel - "LIFNano™" - and so providing a low cost, high value solution to current neuro-inflammatory diseases where today there is no cure.
The Company
The Company revolutionises efficiency for global sustainability of advanced therapies. Now clinical stage, the Company's disruptive technology is clean and entirely cell-free, avoiding the high costs and environmental impact of cell-based therapeutics.
Why LIF ?
LIF* is profoundly neuro-protective and the Company's first treatment indication is Multiple Sclerosis (MS). In vivo trials demonstrate partial reversal of paralysis in preclinical models of MS, confirming targeted delivery of LIF is not only a drug-free natural solution to protect and heal the brain, but also may quench the autoimmune root-cause of MS. A Phase I Clinical Trial is planned 2021/2022 at the end of which the projected valuation of the Company will be $800M.
The Business
The Company's platform technology is protected by suite of patents with exclusive licence for autoimmune, neurodegenerative, and inflammatory diseases. The business model incorporates three free-standing, inter-linked, synergistic pathways:
Firstly, license of LIFNano™ to Pharma across different therapeutic areas (MS initially) and across different territories.
Secondly, licence of cGMP LIFNano™ as a growth factor with unique properties to the expanding growth medium market (size $7.6 billion 2025): this is via the Company's wholly owned subsidary, LIFStem Ltd.
Thirdly, to enter the Respiratory Disease market ($2.8 billion 2026), where LIF is absolutely required to protect the lung against viral pneumonia.
Investors
The Company has retained 100% equity through grants, with virtual management and low internal costs gaining a high value growth trajectory to the clinic. Today, through contracts, the world's best in quality for clinical delivery are engaged. With forecasted ROI exceeding >50, the Company is now open to offers for equity investment.
Please address enquires to Dr Su Metcalfe : s.metcalfe@LIFNano.com
* LIF is short for "Leukaemia Inhibitory Factor" - a growth factor required to support and regulate stem cells.